A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)
Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We conducted a single-arm, phase 2 trial to investigate the efficacy and safety of spartalizumab in patients with refractory esophageal squamous cell carcinoma (ESCC). Patients with histo...
Saved in:
| Main Authors: | Dong Ki Lee, Sook Ryun Park, Yeul Hong Kim, Yun-Gyoo Lee, Su-Jin Shin, Beung-Chul Ahn, Sung Sook Lee, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Min Hee Hong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2371563 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
by: Armando Santoro, et al.
Published: (2024-10-01) -
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
by: Chia-Chi Lin, et al.
Published: (2024-12-01) -
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
by: Hans Gelderblom, et al.
Published: (2020-05-01) -
Cell-Cultured Influenza Vaccine Enhances IFN-γ+ T Cell and Memory T Cell Responses Following A/Victoria/2570/2019 IVR-215 (A/H1N1) Infection
by: Kyu-Ri Kang, et al.
Published: (2024-12-01) -
Probiotic properties of Bacillus licheniformis HN318 and comparison of the effects of its bacterial cells and cultures on growth, immunity and disease resistance of hybrid grouper (Epinephelus polyphekadion♂ × Epinephelus fuscoguttatus♀)
by: Zhenjie Cao, et al.
Published: (2025-02-01)